Integra LifeSciences falls 21% on a $30 million guidance cut; $1.6 billion of net debt is why it hurt

Integra LifeSciences shares fell 21.2% on Friday to close at $12.68, per Nasdaq, after the medical device maker said a July flood at its Cincinnati plant would cost it more sales than it had planned for and cut its full-year outlook. Volume was about 2.7 million shares, more than three times the daily average.

In a preliminary release filed with the SEC, Integra said it expects third-quarter revenue of about $410 million to $412 million and adjusted earnings of $0.55 to $0.59 a share. It lowered its 2026 revenue range to $1.634 billion to $1.654 billion, from $1.654 billion to $1.695 billion, and its adjusted earnings range to $2.30 to $2.40 a share, from $2.40 to $2.50.

The numbers behind the cut

The quarter was at the floor, not below it. In its July results, Integra guided third-quarter revenue to $410 million to $425 million and adjusted earnings to $0.53 to $0.61. Friday's preliminary figures sit at the bottom of the sales range and inside the earnings range. Against the July guide, which called $410 million growth of 2.0%, the quarter works out to roughly 2% to 2.5% growth.

The flood explains most of the full-year cut, not all of it. The midpoint of the revenue range fell by about $30.5 million. Integra puts the flood's hit at about $7 million in the third quarter and $15 million to $20 million in the fourth, or $22 million to $27 million in total. The company said the rest reflects "updated assumptions for the broader business." The top of the new range is now the bottom of the old one.

The plant will not be back until next year. Integra expects full manufacturing at the Cincinnati site, which makes products in its Specialty Surgical Technologies portfolio, during the second quarter of 2027. It said insurance should cover "a substantial portion" of the earnings impact until then, without putting a number on it.

Why a small cut moved the stock so much

With about 77.8 million shares, implied by Nasdaq's market value of $986 million at the close, Friday's $3.41 drop erased about $265 million of equity value. That is close to nine times the cut to the revenue midpoint, and the cut to adjusted earnings was 10 cents a share, or under $8 million on that share count.

The balance sheet is the reason the equity reacts so sharply. At the end of June, Integra reported net debt of $1.6 billion and a total leverage ratio of 4.1 times, against a market value now under $1 billion. Debt is more than 60% of the company's enterprise value on those figures, so a change in expected profit lands on a thin layer of equity.

The cash picture was the one figure Integra kept steady. It still expects operating cash flow of $190 million to $200 million for the year, including more than $85 million in the third quarter, up from $22.8 million in the second.

What traders are watching

Integra will report full third-quarter results later in October. The items to watch are the size of any insurance recovery, whether the fourth-quarter flood estimate holds, and whether the SurgiMend relaunch from its Braintree plant stays on its planned fourth-quarter schedule. The stock's 52-week range is $8.70 to $20.49.

Sources: Integra preliminary Q3 2026 release and Q2 2026 results via SEC EDGAR; Nasdaq quote data. This is market information, not investment advice.